Juan Pedro-Botet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Juan Pedro-Botet has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Albert Goday
Centro de Investigación Biomédica en Red Fisiopatologia de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain
2 shared publications - Juan Jose Chillaron
Department of Endocrinology and Nutrition, Consorci Sanitari Alt Penedès-Garraf, Espirall, 61, 08720 Vilafranca del Penedès, Spain
2 shared publications A Guelar
1 shared publicationA. Soler
Universidad Autónoma de Barcelona
1 shared publication- Alberto Cordero
Faculty of Medicine, Miguel Hernández University, Alicante, Spain; Department of Cardiology, San Juan de Alicante University Hospital, Alicante, Spain
1 shared publication - Alipio Mangas- Rojas
Medicine Department, School of Medicine, University of Cadiz, Cadiz, Spain
1 shared publication
Latest Publications
- Open Access
- 18 March 2013
- Published by Springer Nature in BMC Family Practice
- Vol. 14 (1) , 36
Implementation of Spanish adaptation of the European guidelines on cardiovascular disease prevention in primary care
The successful implementation of cardiovascular disease (CVD) prevention guidelines relies heavily on primary care physicians (PCPs) providing risk factor evaluation, intervention and patient education. The aim of this study was to ascertain the degree of awareness and implementation of the Spanish adaptation of the European guidelines on CVD prevention in clinical practice (CEIPC guidelines) among PCPs.
- 18 March 2013
- Published by Springer Nature in BMC Family Practice
- Vol. 14 (1) , 36
Open AccessImplementation of Spanish adaptation of the European guidelines on cardiovascular disease prevention in primary care
The successful implementation of cardiovascular disease (CVD) prevention guidelines relies heavily on primary care physicians (PCPs) providing risk factor evaluation, intervention and patient education. The aim of this study was to ascertain the degree of awareness and implementation of the Spanish adaptation of the European guidelines on CVD prevention in clinical practice (CEIPC guidelines) among PCPs.
- Open Access
- 13 July 2010
- Published by Wiley in Clinical Cardiology
- Vol. 33 (7) , 418-423
A Very High Prevalence of Low HDL Cholesterol in Spanish Patients With Acute Coronary Syndromes
Background Total and low-density lipoprotein cholesterol (LDL-C) concentrations in coronary artery disease have progressively declined, although high-density lipoprotein cholesterol (HDL-C) has not always been evaluated. The prevalence and related factors of low HDL-C in a cohort of Spanish patients with acute coronary syndromes (ACS) were assessed. Methods Clinical and laboratory data registered at admission and at discharge of 648 patients admitted to coronary care units of 6 Spanish hospitals for ACS between January 2004 and September 2007 were analyzed. Results Low HDL-C (HDL-C < 1.04 mmol/L) was observed in 367 (56.6%) patients. Male gender, smoking, hypertension, diabetes, high body mass index, and triglycerides were related to low HDL-C. Female gender was the strongest protective factor against low HDL-C (0.619; 95% confidence interval [CI]: 0.410–0.934; P = 0.022), whereas high triglycerides (1.653; 95% CI: 1.323–2.064; P < 0.001) followed by previous ischemic disease (1.504; 95% CI: 1.073–2.110; P = 0.018) were the strongest factors associated with low HDL-C. One-third of patients were taking statins at admission, but only 2% were on fibrate therapy. A large increase in statin therapy, but not in other hypolipemiant drug therapy, between admission and discharge was noted in the whole cohort and among patients with low HDL-C. Conclusion Spanish patients with ACS have a very high prevalence of low HDL-C. Male gender, high triglycerides, and previous ischemic disease are strong, independent factors associated with this disorder. As low HDL-C remains almost completely untreated in ACS, strategies to enhance the treatment of this lipoprotein abnormality are urgently required. Copyright © 2010 Wiley Periodicals, Inc.
- 13 July 2010
- Published by Wiley in Clinical Cardiology
- Vol. 33 (7) , 418-423
Open AccessA Very High Prevalence of Low HDL Cholesterol in Spanish Patients With Acute Coronary Syndromes
Background Total and low-density lipoprotein cholesterol (LDL-C) concentrations in coronary artery disease have progressively declined, although high-density lipoprotein cholesterol (HDL-C) has not always been evaluated. The prevalence and related factors of low HDL-C in a cohort of Spanish patients with acute coronary syndromes (ACS) were assessed. Methods Clinical and laboratory data registered at admission and at discharge of 648 patients admitted to coronary care units of 6 Spanish hospitals for ACS between January 2004 and September 2007 were analyzed. Results Low HDL-C (HDL-C < 1.04 mmol/L) was observed in 367 (56.6%) patients. Male gender, smoking, hypertension, diabetes, high body mass index, and triglycerides were related to low HDL-C. Female gender was the strongest protective factor against low HDL-C (0.619; 95% confidence interval [CI]: 0.410–0.934; P = 0.022), whereas high triglycerides (1.653; 95% CI: 1.323–2.064; P < 0.001) followed by previous ischemic disease (1.504; 95% CI: 1.073–2.110; P = 0.018) were the strongest factors associated with low HDL-C. One-third of patients were taking statins at admission, but only 2% were on fibrate therapy. A large increase in statin therapy, but not in other hypolipemiant drug therapy, between admission and discharge was noted in the whole cohort and among patients with low HDL-C. Conclusion Spanish patients with ACS have a very high prevalence of low HDL-C. Male gender, high triglycerides, and previous ischemic disease are strong, independent factors associated with this disorder. As low HDL-C remains almost completely untreated in ACS, strategies to enhance the treatment of this lipoprotein abnormality are urgently required. Copyright © 2010 Wiley Periodicals, Inc.
- Open Access
- 1 September 2009
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (9) , 3530-3534
Estimated Glucose Disposal Rate in Assessment of the Metabolic Syndrome and Microvascular Complications in Patients with Type 1 Diabetes
Objective: The objective of the study was to quantify insulin resistance in type 1 diabetes patients by estimated glucose disposal rate (eGDR), according to the presence or absence of the metabolic syndrome, and its relationship with chronic complications. Design: This was a cross-sectional study in 91 patients with type 1 immune-mediated diabetes managed at an outpatient endocrinology clinic. All participants were Caucasians aged 18 yr or older with type 1 diabetes duration of more than 6 months who had completed the study protocol. Results: Twenty-nine patients met metabolic syndrome criteria, yielding a prevalence of 31.9%. Although no differences in insulin requirements were found between diabetic patients with and without metabolic syndrome, lower eGDR levels, indicating greater insulin resistance, were observed in metabolic syndrome patients compared with those without (6.19 ± 1.5 mg/kg−1 · min−1vs. 9.93 ± 1.6 mg/kg−1 · min−1) (P < 0.001). An eGDR level less than 8.77 mg/kg−1 · min−1 showed 100% sensitivity and 85.2% specificity for metabolic syndrome diagnosis. All patients with diabetes complications had eGDR values below 8.16 mg/kg−1 · min−1. eGDR level was significantly lower in patients with diabetic retinopathy (5.97 ± 1.2 mg/kg−1 · min−1), diabetic neuropathy (5.06 ± 0.4 mg/kg−1 · min−1), or diabetic nephropathy (5.79 ± 1.5 mg/kg−1 · min−1) compared with those without (9.38 ± 2.0 mg/kg−1 · min−1, P < 0.001; 9.26 ± 2.0 mg/kg−1 · min−1, P < 0.001; and 9.19 ± 2.2 mg/kg−1 · min−1, P < 0.001). Conclusions: Insulin resistance is common in type 1 diabetes patients and is associated with microvascular complications. eGDR, as an insulin resistance marker, provides more useful information than other classical variables such as insulin requirements. Estimated glucose disposal rate, as an insulin resistance marker, provides more useful information than other classical variables such as insulin requirements.
- 1 September 2009
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (9) , 3530-3534
Open AccessEstimated Glucose Disposal Rate in Assessment of the Metabolic Syndrome and Microvascular Complications in Patients with Type 1 Diabetes
Objective: The objective of the study was to quantify insulin resistance in type 1 diabetes patients by estimated glucose disposal rate (eGDR), according to the presence or absence of the metabolic syndrome, and its relationship with chronic complications. Design: This was a cross-sectional study in 91 patients with type 1 immune-mediated diabetes managed at an outpatient endocrinology clinic. All participants were Caucasians aged 18 yr or older with type 1 diabetes duration of more than 6 months who had completed the study protocol. Results: Twenty-nine patients met metabolic syndrome criteria, yielding a prevalence of 31.9%. Although no differences in insulin requirements were found between diabetic patients with and without metabolic syndrome, lower eGDR levels, indicating greater insulin resistance, were observed in metabolic syndrome patients compared with those without (6.19 ± 1.5 mg/kg−1 · min−1vs. 9.93 ± 1.6 mg/kg−1 · min−1) (P < 0.001). An eGDR level less than 8.77 mg/kg−1 · min−1 showed 100% sensitivity and 85.2% specificity for metabolic syndrome diagnosis. All patients with diabetes complications had eGDR values below 8.16 mg/kg−1 · min−1. eGDR level was significantly lower in patients with diabetic retinopathy (5.97 ± 1.2 mg/kg−1 · min−1), diabetic neuropathy (5.06 ± 0.4 mg/kg−1 · min−1), or diabetic nephropathy (5.79 ± 1.5 mg/kg−1 · min−1) compared with those without (9.38 ± 2.0 mg/kg−1 · min−1, P < 0.001; 9.26 ± 2.0 mg/kg−1 · min−1, P < 0.001; and 9.19 ± 2.2 mg/kg−1 · min−1, P < 0.001). Conclusions: Insulin resistance is common in type 1 diabetes patients and is associated with microvascular complications. eGDR, as an insulin resistance marker, provides more useful information than other classical variables such as insulin requirements. Estimated glucose disposal rate, as an insulin resistance marker, provides more useful information than other classical variables such as insulin requirements.
- 1 January 2009
- Published by Elsevier in Medicina Clinica
- Vol. 132 (3) , 102-103
Importancia clínica de la modulación terapéutica de las partículas de LDL pequeñas y densas
- 1 January 2009
- Published by Elsevier in Medicina Clinica
- Vol. 132 (3) , 102-103
Importancia clínica de la modulación terapéutica de las partículas de LDL pequeñas y densas
- 1 April 2008
- Published by Elsevier in Medicina Clinica
- Vol. 130 (12) , 466-471
Síndrome metabólico, diabetes mellitus tipo 1 y resistencia a la insulina
- 1 April 2008
- Published by Elsevier in Medicina Clinica
- Vol. 130 (12) , 466-471
Síndrome metabólico, diabetes mellitus tipo 1 y resistencia a la insulina
- 1 November 2005
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 18 (11) , 1396-1401
Hypertension in HIV-Infected Patients: Prevalence and Related Factors
Little is known about hypertension in the HIV-infected population. This study aimed to assess the prevalence of hypertension and related factors in HIV-infected patients. In this prospective cross-sectional study, 710 HIV-infected patients (626 on combination antiretroviral therapy and 84 naive) managed at the outpatient clinic of a tertiary hospital during 2003 and 802 controls completed the study protocol consisting of medical examination and a 6-month follow-up period including three control visits. Hypertension prevalence was 13.1% in HIV-infected patients and 13.5% in the control group. Age (per 10-year increment) (odds ratio [OR]: 1.92; 95% confidence interval [CI]: 1.48-2.48), body mass index (OR: 1.18; 95% CI: 1.10-1.27), and lipoaccumulation pattern of fat redistribution (OR: 2.26; 95% CI: 1.20-4.24) were independently and significantly associated with the presence of hypertension in HIV-infected patients at logistic regression analysis. The present results suggest no meaningful difference in prevalence of hypertension between subjects with and without HIV infection. Thus, the influence of combination antiretroviral therapy appears to have little impact on the prevalence of hypertension.
- 1 November 2005
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 18 (11) , 1396-1401
Hypertension in HIV-Infected Patients: Prevalence and Related Factors
Little is known about hypertension in the HIV-infected population. This study aimed to assess the prevalence of hypertension and related factors in HIV-infected patients. In this prospective cross-sectional study, 710 HIV-infected patients (626 on combination antiretroviral therapy and 84 naive) managed at the outpatient clinic of a tertiary hospital during 2003 and 802 controls completed the study protocol consisting of medical examination and a 6-month follow-up period including three control visits. Hypertension prevalence was 13.1% in HIV-infected patients and 13.5% in the control group. Age (per 10-year increment) (odds ratio [OR]: 1.92; 95% confidence interval [CI]: 1.48-2.48), body mass index (OR: 1.18; 95% CI: 1.10-1.27), and lipoaccumulation pattern of fat redistribution (OR: 2.26; 95% CI: 1.20-4.24) were independently and significantly associated with the presence of hypertension in HIV-infected patients at logistic regression analysis. The present results suggest no meaningful difference in prevalence of hypertension between subjects with and without HIV infection. Thus, the influence of combination antiretroviral therapy appears to have little impact on the prevalence of hypertension.
- 15 June 2004
- Published by Springer Nature in Clinical Rheumatology
- Vol. 23 (6) , 555-556
Pulmonary coinfection by Pneumocystis carinii and Aspergillus fumigatus in a seronegative arthritis patient treated with low-dose methotrexate
- 15 June 2004
- Published by Springer Nature in Clinical Rheumatology
- Vol. 23 (6) , 555-556
Pulmonary coinfection by Pneumocystis carinii and Aspergillus fumigatus in a seronegative arthritis patient treated with low-dose methotrexate
- Open Access
- 1 June 2000
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 14 (6) , 343-345
Decreased endogenous antioxidant enzymatic status in essential hypertension
Several lines of evidence suggest that patients with essential hypertension have impaired endothelial nitric oxide activity and increased superoxide anion production. However, the mechanisms underlying these abnormalities remain unknown. We measured enzymatic superoxide dismutase (SOD) and glutathione peroxidase (GPX) activities in erythrocytes and whole blood, respectively, in 30 newly-diagnosed, normolipidaemic untreated mild hypertensive patients and in 164 age-matched healthy controls. SOD and GPX activities in hypertensive patients (806 ± 225 U/Hb.g and 5491 ± 2073 U/L, respectively) were significantly lower than in the control group (931 ± 202 U/Hb.g and 6669 ± 1560 U/L, respectively) (P < 0.005). no significant association was found between these antioxidant enzyme activities and blood pressure in normotensive controls. in the hypertensives, only log-transformed sod activity showed a significant negative correlation with systolic and diastolic blood pressure (r = 0.37, P < 0.05; r = 0.64, P < 0.0001, respectively). the low endogenous antioxidant enzyme activities observed may in turn result in decreased superoxide anion removal leading to nitric oxide inactivation.
- 1 June 2000
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 14 (6) , 343-345
Open AccessDecreased endogenous antioxidant enzymatic status in essential hypertension
Several lines of evidence suggest that patients with essential hypertension have impaired endothelial nitric oxide activity and increased superoxide anion production. However, the mechanisms underlying these abnormalities remain unknown. We measured enzymatic superoxide dismutase (SOD) and glutathione peroxidase (GPX) activities in erythrocytes and whole blood, respectively, in 30 newly-diagnosed, normolipidaemic untreated mild hypertensive patients and in 164 age-matched healthy controls. SOD and GPX activities in hypertensive patients (806 ± 225 U/Hb.g and 5491 ± 2073 U/L, respectively) were significantly lower than in the control group (931 ± 202 U/Hb.g and 6669 ± 1560 U/L, respectively) (P < 0.005). no significant association was found between these antioxidant enzyme activities and blood pressure in normotensive controls. in the hypertensives, only log-transformed sod activity showed a significant negative correlation with systolic and diastolic blood pressure (r = 0.37, P < 0.05; r = 0.64, P < 0.0001, respectively). the low endogenous antioxidant enzyme activities observed may in turn result in decreased superoxide anion removal leading to nitric oxide inactivation.